News | March 02, 2024
Cipla incorporates JV company in USA
Cipla completes transfer of Generics Business Undertaking
Cipla completes transfer of Generics Business Undertaking
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Cipla and Ethris partner for the development of mRNA-based therapies
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)